Drug Profile

HY 05350

Alternative Names: HY-05350

Latest Information Update: 30 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sichuan Huiyu Pharmaceutical
Class Antineoplastics; Immunotherapies; Trispecific antibodies
Mechanism of Action CD3 antigen stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

24 Jul 2025 Sichuan Huiyu Pharmaceutical plans a phase I/II trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in China (IV, Injection), in July 2025 (NCT07083323)
01 Jul 2025 Sichuan Huiyu Pharmaceutical plans a clinical trial for solid tumors (Late-stage diseases) in China
25 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com